📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 3 — Analytical Methods Validation (TILA-278)

Document ID: M3-AMV
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH Q2(R2)

Analytical Methods Validation — TILA-278

Validation summary for the release and stability-indicating methods for TILA-278 (identity, assay/potency, purity/impurities, and safety tests), demonstrating specificity, accuracy, precision, linearity, range, and robustness per ICH Q2(R2). ICH Q2(R2)/Q6.

TILA-278 is a humanized IgG1 bispecific monoclonal antibody produced by fed-batch culture of a recombinant Chinese hamster ovary (CHO) cell line and purified through a platform sequence anchored by Protein A affinity capture followed by orthogonal polishing chromatography. One arm antagonizes TL1A (TNFSF15) and the second arm agonizes the IL-22 receptor (IL-22R); the analytical control strategy is therefore designed to confirm both the correct assembly of the bispecific format and the independent, simultaneous functionality of each arm. The drug product is a subcutaneous presentation. Because the molecule is a biotechnology-derived protein, the panel of analytical procedures and their validation follow ICH Q2(R2) for validation characteristics, ICH Q6B for the selection and justification of specifications and the associated procedures, ICH Q5A(R2) for adventitious-agent and viral-safety testing, and ICH Q5C for the stability-indicating design; compendial procedures (USP, Ph. Eur., JP) are used where harmonized methods exist. ICH Q2(R2)/Q6B/Q5A(R2)/Q5C.

Scope and Regulatory Basis

This report summarizes validation of the analytical procedures used to release and monitor the stability of TILA-278 drug substance and drug product, in support of the Biologics License Application filed under 21 CFR 601. Each procedure was validated for the characteristics relevant to its purpose using the definitions and acceptance framework of ICH Q2(R2). Quantitative procedures (assay, potency, quantitative impurity methods) were assessed for specificity, accuracy, precision (repeatability and intermediate precision), linearity, range, and — where relevant to trace-level impurities — detection limit (DL) and quantitation limit (QL). Limit tests were validated for specificity and DL. Identity procedures were validated for specificity. Robustness was established during development and confirmed by defined system-suitability criteria applied at every routine use. The procedures are demonstrated to be fit for their intended use and to remain valid across the ranges of drug substance and drug product encountered in manufacturing, release, and shelf-life monitoring.

Molecule and Analytical Control Strategy

The bispecific architecture introduces quality attributes beyond those of a conventional monospecific IgG1, and the analytical panel is structured to address them. Identity confirms both antigen-binding specificities and the intended chain composition. Potency is measured by a matrix of complementary bioassays that independently interrogate TL1A antagonism and IL-22R agonism, together with a bridging assay that confirms a single molecule engages both antigens simultaneously. Purity and impurity methods resolve product-related variants common to all mAbs (aggregates, fragments, charge and glycan heterogeneity) and, in addition, the format-specific species characteristic of bispecific assembly — homodimers, half-antibodies, and mispaired chains. Process-related impurity methods control residual CHO host-cell protein (HCP), residual host-cell DNA, and leached Protein A ligand. Safety tests address microbiological and endotoxin control appropriate to a sterile parenteral. The strategy applies a tiered approach in which routine release and stability procedures are supported by orthogonal characterization methods (for example intact and subunit mass spectrometry, SEC-MALS, and analytical ultracentrifugation) that underpin structural understanding without necessarily appearing on the specification.

Reference Standards and System Suitability

A two-tiered reference standard system is used. A primary reference standard, extensively characterized for identity, structure, purity, and both potency activities, is the anchor of the potency and purity value assignments; a working (in-use) reference standard is qualified against the primary standard and used in routine testing. Traceability, qualification, and requalification of each tier are documented, and the potency of the primary standard is assigned relative to a well-characterized lot. Every quantitative and comparative procedure carries predefined system-suitability criteria — for chromatographic methods, resolution, tailing, and reference-standard reproducibility; for electrophoretic methods, migration-time reproducibility and marker resolution; for bioassays, curve goodness-of-fit, EC50 within an expected window, an adequate signal-to-background window, and parallelism between test and reference curves. Runs that fail system suitability are invalid and are not reported as results.

Validation Parameters and Acceptance Criteria (ICH Q2(R2))

Validation acceptance criteria were pre-specified in approved protocols and derived from method capability observed during development and from the intended specification limits. For quantitative content and impurity procedures, accuracy was demonstrated by recovery across the reporting range (typically 90–110% for physicochemical content methods and 80–125% relative-potency recovery for bioassays), repeatability and intermediate precision were expressed as %RSD or geometric %CV, linearity was demonstrated with a coefficient of determination generally ≥ 0.99 for chromatographic and spectroscopic procedures, and DL/QL were established for trace impurity peaks and residuals. Specificity was demonstrated using blank matrices, individual impurity/degradant standards, and stressed material. The evaluation confirmed that each procedure met its pre-specified criteria; representative outcomes are consolidated in the Validation Summary Matrix below.

Identity Methods

Identity of TILA-278 is established by a combination of orthogonal procedures that together confirm both binding specificities and the intended primary structure. A dual-antigen binding identity assay confirms reactivity to both TL1A and IL-22R; peptide mapping by LC-UV/MS confirms the amino-acid sequence and characteristic complementarity-determining-region peptides for each arm; intact and reduced/subunit mass analysis by LC-MS confirms the expected masses of the assembled bispecific and of its constituent heavy- and light-chain subunits, providing direct evidence of correct chain composition. Charge-based identity (iCIEF/imaged capillary isoelectric focusing) confirms the characteristic isoelectric profile. Each identity procedure was validated for specificity, demonstrating unambiguous discrimination of TILA-278 from a relevant monospecific control antibody and from blank matrix, with no interference from formulation excipients. ICH Q6B.

Potency and Binding Methods

Because both antigen-binding activities are essential to the intended pharmacology, potency is defined by a matrix of bioassays rather than a single measure. TL1A antagonism is quantified in a cell-based reporter assay in which a DR3-responsive reporter cell line is stimulated with recombinant TL1A; TILA-278 neutralizes the TL1A-driven reporter signal, and relative potency versus the reference standard is derived from a four-parameter logistic parallel-line analysis. IL-22R agonism is quantified in a STAT3-responsive reporter cell line in which TILA-278 drives STAT3-dependent reporter expression, with relative potency again determined against the reference standard. A bispecific bridging binding assay confirms that a single molecule simultaneously engages TL1A and IL-22R, verifying the intended dual-target format. Kinetic binding to human TL1A and human IL-22R, and to the cynomolgus monkey orthologs, is characterized by surface plasmon resonance / bio-layer interferometry; cross-reactivity to the cynomolgus orthologs supports the pharmacological relevance of the nonclinical species. The potency procedures were validated for specificity (no response to matrix or to a non-cognate control), relative accuracy (recovery of blended/spiked samples across the range, target 80–125%), repeatability and intermediate precision (geometric %CV consistent with bioassay capability), linearity of measured versus nominal relative potency, and a validated reporting range (representatively 50–150%). System suitability governs each run through reference-curve fit, EC50 acceptance, signal window, and test-to-reference parallelism. ICH Q6B/Q2(R2).

Product-Related Purity and Impurities

Size heterogeneity is monitored by size-exclusion chromatography (SEC-HPLC), reporting monomer, high-molecular-weight (HMW aggregate/dimer), and low-molecular-weight (LMW) species; the method was validated for specificity (baseline resolution of HMW from monomer), precision, accuracy by mass balance, linearity of load, and QL for HMW and LMW peaks. Orthogonal SEC-MALS and analytical ultracentrifugation confirm the SEC-HPLC aggregate assignment in characterization. Size purity is further resolved by reduced and non-reduced CE-SDS: the reduced method quantifies heavy and light chains and non-glycosylated heavy chain, while the non-reduced method quantifies the intact bispecific and any fragments, including half-antibody — an attribute of particular relevance to a bispecific and a direct readout of correct covalent assembly. Charge heterogeneity is monitored by iCIEF and/or cation-exchange chromatography (CEX-HPLC), reporting acidic, main, and basic variant groups arising from deamidation, C-terminal lysine, and related modifications. N-linked glycosylation is profiled by HILIC-UPLC with fluorescence detection of released, labeled glycans, reporting the major CHO-derived structures (including fucosylated biantennary forms, afucosylated species, and high-mannose content) relevant to Fc-mediated function and clearance. Bispecific format-related impurities — homodimers, mispaired light chains, and half-molecules — are characterized and controlled through intact/subunit LC-MS together with orthogonal chromatographic resolution (for example hydrophobic-interaction and ion-exchange separations). Each quantitative purity procedure was validated for specificity, precision, accuracy (spike/blend recovery where applicable), linearity, range, and QL for impurity peaks, and each was confirmed stability-indicating (see below). ICH Q6B/Q5A(R2).

Process-Related Impurities and Adventitious Agents

Residual CHO host-cell protein is measured by an immunoassay (HCP ELISA) qualified with a demonstrated antigen-coverage assessment; the procedure was validated for dilutional linearity, spike recovery (representatively 50–150%), and DL/QL at the ng/mg level. Residual host-cell DNA is measured by a CHO-specific quantitative PCR method validated for linearity across the working log range (coefficient of determination ≥ 0.98), accuracy by spike recovery, and QL at the picogram level, consistent with the residual-DNA control expectations for parenteral biotechnology products. Leached Protein A ligand is measured by ELISA validated for spike recovery, linearity, and QL (ng/mg). Adventitious-agent and viral-safety testing follows ICH Q5A(R2): bioburden, endotoxin, mycoplasma (compendial culture plus nucleic-acid-based detection), and in vitro adventitious virus and retrovirus assessment are applied at the appropriate manufacturing stages using compendial or validated procedures, and the outputs integrate with the viral clearance evaluation of the downstream process. ICH Q5A(R2)/Q6B.

General Tests, Quantity, and Safety Tests

Protein concentration is determined by UV absorbance at 280 nm using the determined extinction coefficient, validated for linearity, accuracy, and precision across the working range. General quality tests include appearance, color and clarity/opalescence, visible and sub-visible particulate matter (light obscuration per USP <788> supported by micro-flow imaging), pH, osmolality, polysorbate content, excipient assays, extractable/deliverable volume, and container-closure integrity. Bacterial endotoxin is measured by a kinetic chromogenic LAL procedure with a validated non-interfering dilution and positive-product-control recovery within the accepted 50–200% window (USP <85>). Bioburden (USP <61>/<62>) and sterility of the drug product (USP <71> / Ph. Eur. 2.6.1) were validated for method suitability, confirming absence of inhibition of microbial recovery. These procedures collectively establish the microbiological and physical quality expected of a sterile subcutaneous parenteral. USP <85>/<71>/<788>; ICH Q6B.

Robustness, Intermediate Precision, and Method Lifecycle

Robustness was evaluated during development by deliberate variation of critical procedural parameters (for the chromatographic methods, mobile-phase composition, column temperature, and flow; for the electrophoretic methods, sample preparation and separation conditions; for the bioassays, cell passage, incubation time, and reagent lots), and the resulting knowledge was codified into system-suitability criteria and controlled procedural ranges. Intermediate precision was assessed across analysts, days, instruments, and reference-standard/reagent lots, confirming that reportable results are reproducible under normal operating variability. Ongoing analytical-procedure lifecycle management — periodic system-suitability trending, reference-standard requalification, and reagent qualification — maintains the validated state of each method through the product lifecycle.

Method Transfer and Co-Validation

Procedures deployed at the quality-control and commercial testing laboratories were transferred under protocols with predefined acceptance criteria, using co-validation or comparative-testing designs in which the sending and receiving laboratories analyze common material and demonstrate equivalent results within pre-specified limits. Transfer acceptance was met for the identity, potency, purity/impurity, and safety procedures, confirming that the validated performance is reproduced at the sites responsible for release and stability testing.

Validation Summary Matrix

Analytical procedure	Attribute class	Validated characteristics (ICH Q2(R2))	Representative acceptance criterion	Outcome
Peptide mapping (LC-UV/MS)	Identity	Specificity	Characteristic map matches reference; distinct from control mAb	Met
Intact/subunit LC-MS	Identity / composition	Specificity	Observed masses match theoretical for assembled molecule and subunits	Met
Dual-antigen binding identity	Identity	Specificity	Positive reactivity to both TL1A and IL-22R	Met
TL1A antagonism bioassay	Potency	Specificity, accuracy, precision, linearity, range	Relative potency recovery 80–125%; range 50–150%	Met
IL-22R agonism bioassay	Potency	Specificity, accuracy, precision, linearity, range	Relative potency recovery 80–125%; range 50–150%	Met
Bispecific bridging assay	Potency / format	Specificity	Simultaneous dual-antigen engagement confirmed	Met
SPR/BLI binding kinetics	Characterization	Specificity, precision	Kinetic constants within qualified ranges; cyno cross-reactivity confirmed	Met
SEC-HPLC	Purity (size)	Specificity, precision, accuracy, linearity, range, QL	Monomer/HMW baseline resolved; QL for HMW established	Met
CE-SDS (reduced / non-reduced)	Purity (size)	Specificity, precision, linearity, range, QL	Half-antibody and fragments resolved and quantifiable	Met
iCIEF / CEX-HPLC	Purity (charge)	Specificity, precision, range, QL	Acidic/main/basic groups resolved and reproducible	Met
HILIC-UPLC-FLR glycan map	Purity (glycan)	Specificity, precision	Major glycans resolved; profile reproducible	Met
HCP ELISA	Process impurity	Specificity, accuracy, linearity, DL/QL	Spike recovery 50–150%; QL at ng/mg	Met
Residual DNA qPCR	Process impurity	Accuracy, linearity, DL/QL	Linearity R² ≥ 0.98; QL at pg level	Met
Residual Protein A ELISA	Process impurity	Accuracy, linearity, QL	Spike recovery within limits; QL at ng/mg	Met
Protein concentration (A280)	Quantity	Accuracy, precision, linearity	Linear across working range; accurate and precise	Met
Bacterial endotoxin (LAL)	Safety	Specificity (non-interference), DL	PPC recovery 50–200% at non-interfering dilution	Met
Bioburden / Sterility	Safety	Method suitability (specificity)	No inhibition of microbial recovery	Met

Conclusion

Stability-indicating capability was demonstrated by analysis of samples subjected to representative stress conditions — thermal, low- and high-pH, oxidative, photostability, and mechanical agitation — confirming that the purity and potency procedures detect and quantify the relevant degradation pathways (aggregation, fragmentation and half-molecule formation, deamidation and other charge changes, oxidation, and loss of TL1A- or IL-22R-directed activity). All release and stability-indicating procedures met their pre-specified validation acceptance criteria and are demonstrated to be specific, accurate, precise, linear, and appropriately sensitive across their validated ranges, in accordance with ICH Q2(R2). The validated procedures are fit for their intended use in controlling identity, potency, purity/impurities, and safety of TILA-278 drug substance and drug product throughout manufacture and shelf life, and support the specifications and stability program described elsewhere in Module 3. ICH Q2(R2)/Q6B/Q5C.